First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
News|Articles|February 13, 2019
Yupelri for Chronic Obstructive Pulmonary Disease
Author(s)Drew Boxler
Advertisement
Yupelri (revefenacin, Mylan®)
Indications: Patients with chronic obstructive pulmonary disease
Dosage: One 175 mcg vial (3 mL) once daily.
Contraindications: hypersensitivity to revefenacin or any component of this product.
Advertisement
Related to this article
The once daily tablet is expected to reach US patients in October 2026.
The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
Advertisement
Advertisement
Trending on Drug Topics
1
What Is HIV PrEP and Who Needs It Most?
2
Community Pharmacists Build Trust and Improve Patient Health
3
Normal vs. Concerning COVID-19 Vaccine Reactions: A Pharmacist's Guide
4
Why Rural Pharmacies Are Essential Infrastructure in US Health Care
5